Loading...
XNYS
PRGO
Market cap2.18bUSD
Oct 30, Last price  
15.78USD
1D
-0.75%
1Q
56.08%
Jan 2017
-81.04%
Name

Perrigo Company PLC

Chart & performance

D1W1MN
XNYS:PRGO chart
P/E
—
P/S
0.51
EPS
—
Vol. 1Y
57.12%
Shs. 5Y
0.35%
Rev. 5Y
0.79%
Div Yld LY
7.35%
Div Yld TTM
7.35%
Revenues
4.25b
-2.75%
1,366,821,0001,447,428,0001,822,131,0002,006,862,0002,268,870,0002,755,029,0003,173,249,0003,539,800,0004,060,800,0004,603,900,0005,280,600,0004,946,200,0004,731,700,0003,869,900,0004,088,200,0004,138,700,0004,451,600,0004,655,600,0004,373,400,0004,253,100,000
Net income
-1.43b
L+729.69%
71,400,00073,797,000135,773,000144,049,000222,546,000339,197,000401,613,000441,900,000205,300,000127,900,000-4,012,800,000119,600,000131,000,000146,100,000-162,600,000-68,900,000-140,600,000-12,700,000-171,800,000-1,425,400,000
CFO
239m
-34.28%
126,531,000128,923,000248,307,000258,345,000314,173,000373,961,000513,376,000553,800,000693,500,0001,198,300,000654,900,000698,900,000593,000,000387,800,000636,200,000156,300,000307,300,000405,500,000362,900,000238,500,000
Dividend
Nov 27, 20260.29 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Related entities

Subsidiaries (9)
GALPHARM INTERNATIONAL LIMITED
OMEGA PHARMA BELGIUM
OMEGA PHARMA INVEST NV
OMEGA PHARMA NV
PERRIGO CAPITAL
PERRIGO FINANCE UNLIMITED COMPANY
Perrigo Investments, LLC
PERRIGO UK ACQUISITION LIMITED
WRAFTON LABORATORIES LIMITED

Key people

Patrick Lockwood-Taylor
President, Chief Executive Officer, Director · since 2023
Eduardo Bezerra
Chief Financial Officer, Executive Vice President · since 2022
David Ball
Executive Vice President, Chief Brand and Digital Officer · since 2024
Roberto Khoury
Executive Vice President, Chief Commercial Officer · since 2025
Abigail Lennox
Executive Vice President, Chief Scientific Officer · since 2025
Robert Willis
Chief Human Resources Officer, Executive Vice President · since 2019
Matt Winterman
Executive Vice President - Product Supply, Operations Strategy and Transformation Officer · since 2025
Charles Atkinson
Executive Vice President, General Counsel, Company Secretary · since 2024
Independent Director · since 2017
Orlando Ashford
Independent Chairman of the Board · since 2022
Julia Brown
Independent Director · since 2023
Kevin Egan
Independent Director · since 2025
Independent Director · since 2017
Independent Director · since 2017
Independent Director · since 2022
Independent Director · since 2014
Independent Director · since 2016
Independent Director · since 2025
IPO date
Dec 17, 1991
Employees
8,900
Domiciled in
IE
Incorporated in
IE
Headquarters & legal address
THE SHARP BUILDING
HOGAN PLACE
DUBLIN 2
DUBLIN, D D02 TY74
IE
Previous name
BLISFONT LIMITED
Previous name
PERRIGO COMPANY LIMITE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT